Your browser doesn't support javascript.
loading
A Unique Case Report of Infant-Type Hemispheric Glioma (Gliosarcoma Subtype) with TPR-NTRK1 Fusion Treated with Larotrectinib.
Mançano, Bruna Minniti; Dos Reis, Mariana Bisarro; Moreno, Daniel Antunes; de Paula, Flávia Escremim; de Almeida Junior, Carlos Roberto; Cavalcante, Carlos Eduardo Bezerra; Zanon, Maicon Fernando; Santana, Iara Viana Vidigal; Matsushita, Marcus de Medeiros; Reis, Rui Manuel.
Affiliation
  • Mançano BM; Departament of Pediatric Oncology, Barretos Cancer Hospital, Barretos, Brazil.
  • Dos Reis MB; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.
  • Moreno DA; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.
  • de Paula FE; Molecular Diagnostic Laboratory, Barretos Cancer Hospital, Barretos, Brazil.
  • de Almeida Junior CR; Department of Pediatric Neurosurgery, Barretos Cancer Hospital, Barretos, Brazil.
  • Cavalcante CEB; Department of Pediatric Radiology, Barretos Cancer Hospital, Barretos, Brazil.
  • Zanon MF; Molecular Diagnostic Laboratory, Barretos Cancer Hospital, Barretos, Brazil.
  • Santana IVV; Molecular Diagnostic Laboratory, Barretos Cancer Hospital, Barretos, Brazil.
  • Matsushita MM; Department of Pathology, Barretos Cancer Hospital, Barretos, Brazil.
  • Reis RM; Department of Pathology, Barretos Cancer Hospital, Barretos, Brazil.
Pathobiology ; 89(3): 178-185, 2022.
Article in En | MEDLINE | ID: mdl-35034013
ABSTRACT
Herein, we present a rare case of a nine-month-old boy diagnosed with infant-type hemispheric glioma (gliosarcoma subtype) at the left frontal lobe. Following subtotal resection, the patient started chemotherapy with the BABY POG protocol. We describe the clinical diagnosis, histological characteristics, radiological features, molecular aspects, and management of this tumor. A comprehensive molecular analysis on the tumor tissue showed a TPR-NTRK1 gene fusion. The patient was treated with a TRK inhibitor, larotrectinib, and exhibited a stable disease with residual lesion following 8 months of target therapy. The present study is the first report of an infantile gliosarcoma harboring NTRK1 rearrangement treated with larotrectinib.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Astrocytoma / Gliosarcoma / Glioma Type of study: Guideline Limits: Humans / Infant / Male Language: En Journal: Pathobiology Journal subject: PATOLOGIA Year: 2022 Document type: Article Affiliation country: Brazil

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Astrocytoma / Gliosarcoma / Glioma Type of study: Guideline Limits: Humans / Infant / Male Language: En Journal: Pathobiology Journal subject: PATOLOGIA Year: 2022 Document type: Article Affiliation country: Brazil